Company news

Vistagen Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Vistagen Reports Fiscal Year 2025 First Quarter Financial Results and Corporate Update

August 12, 2024

Vistagen Broadens PH80 Global Intellectual Property Portfolio with New Patents for the Treatment of Migraine

July 8, 2024

Vistagen Awarded Mental Health America’s Platinum Bell Seal for Workplace Mental Health for the Second Consecutive Year

June 26, 2024

Vistagen Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

June 10, 2024

Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue

April 24, 2024

Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2

March 31, 2024

Vistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate Update

February 12, 2024

Vistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic Pain

December 26, 2023

Vistagen Provides Corporate Update and Reports Fiscal 2024 Second Quarter Financial Results

November 8, 2023

Vistagen Announces Pricing of $100 Million Underwritten Offering

October 1, 2023

Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder

September 11, 2023

Vistagen and Fuji Enter Exclusive Negotiation Agreement for a Potential License to Develop and Commercialize Vistagen’s Investigational Menopausal Hot Flash Therapy, PH80 Nasal Spray, in Japan

September 4, 2023

Vistagen Appoints Cindy Anderson as Chief Financial Officer

August 21, 2023

Vistagen Announces Positive Top-Line Results from Phase 3 PALISADE-2 Trial of Fasedienol (PH94B) Nasal Spray in Social Anxiety Disorder

August 6, 2023

Vistagen Reports New Preclinical Data Supporting Itruvone (PH10) Nasal Spray’s Potential Antidepressant Activity via Peripheral Nasal Neurons without Entry into the Brain

July 16, 2023

Vistagen Receives Notice of Allowance for AV-101 Canadian Patent for Treatment of Dyskinesia Related to Levodopa Therapy for Parkinson’s Disease

July 12, 2023

Vistagen Provides Corporate Update and Reports Fiscal Year 2023 Financial Results

June 27, 2023

Vistagen to Announce Fiscal Year 2023 Financial Results and Provide Corporate Update Conference Call on June 28, 2023

June 26, 2023

Vistagen Regains Full Compliance with Nasdaq Listing Requirements

June 22, 2023

Vistagen Announces Results of Successful U.S. Phase 1 Study of Itruvone (PH10), Enabling U.S. Phase 2B Development for Treatment of Major Depressive Disorder

June 20, 2023

Vistagen Announces European Patent Office Intention to Grant New PH80 Nasal Spray Patent for the Treatment of Migraine

June 12, 2023

Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 in Women Diagnosed with Menopausal Hot Flashes

June 6, 2023

Vistagen Announces Stockholder-Approved Reverse Stock Split

June 5, 2023

Vistagen Receives New European Patent for AV-101

April 5, 2023

Vistagen Announces Positive Data in Fasedienol (PH94B) Phase 3 Open-Label Study in Adults with Social Anxiety Disorder

March 21, 2023

Vistagen Announces Completion of Last Patient, Last Visit in Phase 1 Clinical Trial of Itruvone (PH10), an Investigational Pherine Nasal Spray for Major Depressive Disorder

March 7, 2023

Vistagen Announces Issuance of U.S. Patent for PH80 Nasal Spray for Treatment of Migraine

February 28, 2023

Vistagen Provides Corporate Update and Reports Fiscal 2023 Third Quarter Financial Results

February 6, 2023

Vistagen to Report Fiscal Year 2023 Third Quarter Financial Results on February 7, 2023

February 5, 2023

Vistagen Announces Closing of Pherin Pharmaceuticals Acquisition

February 1, 2023

Vistagen Announces First Participants Dosed in Phase 1 Clinical Trial of PH10, an Investigational Pherine Nasal Spray for Major Depressive Disorder

January 23, 2023

Vistagen Poised To Begin Phase 1 Trial Of A Fast-Acting Antidepressant Nasal Spray In First Quarter Of 2023

January 18, 2023

Vistagen Announces Completion of Last Patient, Last Visit in Phase 2 Clinical Trial of PH94B for the Treatment of Adjustment Disorder with Anxiety

January 9, 2023

Vistagen Advances Intellectual Property Program to Expand Patent Protection for PH94B to Include Treatment of Adjustment Disorder

December 29, 2022

Vistagen to Acquire Pherin Pharmaceuticals

December 20, 2022

Vistagen Receives FDA Fast Track Designation for Development of PH10 to Treat Major Depressive Disorder

December 5, 2022

Vistagen Receives FDA “Study May Proceed” Letter Under its Investigational New Drug Application for PH10 to Treat Major Depressive Disorder

November 29, 2022

Vistagen Announces Publication in Cells Demonstrating AV-101’s Potential for Treating Levodopa-Induced Dyskinesia in Patients with Parkinson's Disease

November 16, 2022

Vistagen Reports Second Quarter Financial Results and Provides Corporate Update

November 9, 2022

Vistagen to Report Fiscal Year 2023 Second Quarter Financial Results on November 10, 2022

November 3, 2022

Vistagen Announces Results of Voting from 2022 Annual Meeting of Stockholders and Partial Adjournment to October 28, 2022

October 18, 2022

Vistagen Announces the Two Leading Proxy Advisory Firms, Institutional Shareholder Services and Glass Lewis, Recommend Stockholders Vote “FOR” Proposal No. 5 to Provide its Board with the Option to Implement a Future Reverse Stock Split, if Necessary

October 5, 2022

Vistagen to Proceed with PALISADE-2 Phase 3 Clinical Trial of PH94B in Social Anxiety Disorder following Interim Analysis

September 7, 2022

VistaGen Therapeutics Reports First Quarter Financial Results and Provides Corporate Update

August 10, 2022

VistaGen Announces Topline Results from PALISADE-1 Phase 3 Clinical Trial for Investigational Drug PH94B

July 21, 2022

VistaGen Therapeutics Reports Fiscal Year 2022 Financial Results and Provides Corporate Update

June 22, 2022

VistaGen Announces Completion of PALISADE-1 Phase 3 Clinical Study of PH94B for the Acute Treatment of Social Anxiety Disorder

June 21, 2022

VistaGen Therapeutics to Report Fiscal Year 2022 Financial Results on June 23, 2022

June 16, 2022

VistaGen to Present PH94B Exploratory Phase 2A Research Program for Adjustment Disorder with Anxiety at American Society for Clinical Psychopharmacology Annual Meeting

June 1, 2022

VistaGen Announces Key Regulatory Update on PH94B for the Acute Treatment of Social Anxiety Disorder

May 4, 2022

← Newer news releases · Older news releases →

Calls

The 5 newest of 19 calls. Every call is listed under its year.

Decks

The 5 newest of 33 decks. Every deck is listed under its year.